Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIB101
- Development stage
- Unknown
- Lead developer
- Noile-Immune Biotech
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
NIB101 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Noile-Immune Biotech. It consists of a patient’s own T lymphocytes genetically modified to express a CAR targeting the tumor-associated antigen GM2 (ganglioside M2), and also engineered to express interleukin-7 (IL-7) and CCL19, which are intended to enhance proliferation and migration of the infused cells. The primary mechanism of action involves immunologic cytotoxicity against GM2-positive tumor cells. NIB101 is being investigated for the treatment of advanced malignant solid neoplasms, particularly in patients with advanced solid tumors expressing GM2 who have failed standard therapies.
- Other names
- autologous IL-7/CCL19-expressing anti-GM2 CAR T cells
02
Targets
GM2 (Ganglioside GM2)
Beyond the preview
Go deeper on NIB101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIB101.